moracizine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| diphenylmethyl piperazine derivatives | 1842 | 31883-05-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.75 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 35.09 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 38 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 19, 1990 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BG01 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Other antiarrhythmics, class I and III |
| FDA EPC | N0000175426 | Antiarrhythmic |
| CHEBI has role | CHEBI:38070 | antiarrhythmic agent |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ventricular arrhythmia | indication | 44103008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.75 | acidic |
| pKa2 | 6.21 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019551 | VUID |
| N0000179669 | NUI |
| D02087 | KEGG_DRUG |
| 29560-58-5 | SECONDARY_CAS_RN |
| 4019551 | VANDF |
| 4019845 | VANDF |
| C0079856 | UMLSCUI |
| CHEBI:6997 | CHEBI |
| CHEMBL1075 | ChEMBL_ID |
| CHEMBL1200334 | ChEMBL_ID |
| DB00680 | DRUGBANK_ID |
| 34633 | PUBCHEM_CID |
| 7244 | IUPHAR_LIGAND_ID |
| 151721 | RXNORM |
| 1620 | MMSL |
| 5135 | MMSL |
| d00307 | MMSL |
| 003553 | NDDF |
| 004488 | NDDF |
| 108489008 | SNOMEDCT_US |
| 350598002 | SNOMEDCT_US |
| 373726009 | SNOMEDCT_US |
| D016293 | MESH_DESCRIPTOR_UI |
| 2998 | INN_ID |
| 71OK3Z1ESP | UNII |
Pharmaceutical products:
None